46 Chapter 2 Supplement 2 - Characteristics of the included studies First author Year Country N Disease group Age (min) Age (max) Used method* Setting Abrines Jaume [1] 2015 United Kingdom 36 Multiple disease groups 4 13 2 Intervention development Adams [2] 2010 Canada 80 Multiple disease groups 5 18 1,4 Clinical care Akard [3] 2013 United States 8 Oncology 7 12 1 Intervention development Alderfer [4] 2017 United States 12 Oncology 12 25 1 Clinical care Alderson [5] 2006 United Kingdom 24 Diabetes 3 12 1 Clinical care Alvarez [6] 2020 United States 8 Hospital admission 7 15 1 Clinical care Ammerlaan [7] 2015 The Netherlands 13 Juvenile Idiopathic Arthritis 16 25 1 Clinical care Anderson [8] 2017 United Kingdom 6 Transplantation 15 18 1 Clinical care Anderzén-Carlsson [9] 2012 Sweden 6 Oncology 14 16 1 Clinical care Angstrom-Brannstrom [10] 2008 Sweden 7 Multiple disease groups 4 10 1,3 Clinical care Applebaum [11] 2013 United States 20 Multiple disease groups 13 21 2 Clinical care Arruda-Colli [12] 2015 Brazil 8 Oncology 5 12 3 Clinical care Arvidsson [13] 2016 Sweden 5 Oncology 6 11 1,3,8 Intervention development Bagley [14] 2007 United States 42 Multiple disease groups 5 15 1 Research Barned [15] 2018 Canada 25 Gastrointestinal diseases 10 17 1 Research Baron [16] 2011 Australia 26 Oncology 4;6 8;2 1 Clinical care Beck [17] 2014 Canada 7 Hematological disorders 10 18 2 Clinical care Belsky [18] 2020 United States 22 Oncology 15 30 1 Intervention development Belsky [19] 2020 United States 20 Oncology 10 28 1 Clinical care Bemmels [20] 2013 United States 10 Surgery 12 18 1 Clinical care Berkwitt [21] 2015 United States 22 Multiple disease groups 7 18 1 Clinical care Bice [22] 2019 United States 16 Hospital admission 4 8 1 Intervention development Black [23] 1995 Australia 104 Hospital admission 12 18 1 Clinical care Board [24] 2005 United States 21 Hospital admission 7 12 1 Clinical care Boisen [25] 2015 Denmark NR Oncology NR NR 8 Clinical care
RkJQdWJsaXNoZXIy MTk4NDMw